Private Equity Is Accelerating in Medical Aesthetics: What Founders Should Know Before Selling

So, Why Is Your Phone Ringing?

If you own a med spa, an aesthetic plastic surgery practice, a cosmetic dermatology group, or a longevity clinic built around hormone therapy, peptides, and medical weight loss, you have probably noticed your inbox getting crowded. A private equity associate wants to “learn more about your story.” An MSO you’ve never heard of asks whether you’d consider a partnership. A competitor two exits down the highway just announced it joined a national platform. And somehow, the person on the other end of a cold call already knows your approximate revenue, how many injectors you employ, and that you opened a second location last spring.

This interest is not random.

Medical aesthetics has become one of the most aggressively courted corners of healthcare services, and the institutional buyers calling you have done their homework. The real question is whether you’ve done yours.

This is not meant as a scare tactic; it reflects the informational asymmetry at the heart of most preliminary conversations, where a buyer with dozens of acquisitions under its belt, a team of analysts, and established lending relationships sits across from a founder who will likely sell only one business in their lifetime. Before considering how to level the playing field, it’s important to understand why buyers are so interested in the first place.

Why Capital Keeps Chasing Aesthetics

Consider the broader healthcare landscape. Most of healthcare depends heavily on reimbursement. A single CMS rule change can shave points off margin overnight, and commercial payer contracting is a persistent administrative challenge. Aesthetics largely sidesteps that exposure. It is cash-pay, consumer-driven, and anchored by recurring visits. This produces a revenue profile that more closely resembles a premium consumer subscription business than a conventional physician practice dependent on fee schedules.

The numbers support the enthusiasm. The American Med Spa Association (AmSpa) pegs U.S. medical aesthetics at more than $17 billion in annual revenue, growing by over $1 billion a year, and its survey data shows repeat-patient rates climbing to roughly 73%. Yet the market remains strikingly fragmented. AmSpa counted about 10,500 med spa locations in its most recent census, roughly four out of five operators run a single location, and industry estimates put private equity ownership at only around 3% to 4% of the market. For a buyer whose strategy depends on stitching smaller operators together into something bigger (and more valuable), that combination of growth and fragmentation is especially attractive.

The top of the market tells the same story. In June 2026, Reuters reported that Ares-backed LaserAway was exploring a sale that could value the chain at more than $2 billion, on roughly $150 million of EBITDA and more than 200 clinics. Ares first invested in 2021, when LaserAway had 74 locations. That trajectory is worth examining, because it explains the math behind the calls you’re getting: platforms buy at one multiple, grow, professionalize, and sell at a higher one. Your practice is a potential input to that equation. The question is who captures the spread.

The definition of “aesthetics” also continues to expand. Today’s buyers are evaluating:

• Multi-location med spas generating eight figures in revenue
• Aesthetic plastic surgery practices with months-long surgical backlogs
• Cosmetic dermatology groups pairing injectables and energy-based devices with medical derm
• Membership-based hormone and peptide clinics with subscription-style revenue
• Physician-led medical weight loss programs
• Longevity and performance medicine businesses with deeply loyal (and high-spending) clients

An important distinction when it comes to valuation is that not all revenue is treated equally. Medical weight loss is the clearest example. Semaglutide and tirzepatide have been off the FDA shortage list since early 2025, and in April 2026 the agency proposed excluding both from the 503B bulks list, so sophisticated buyers now scrutinize compounded GLP-1 revenue line by line and frequently haircut it in their valuation models.

Peptides face a similar, murkier regulatory environment that has shifted more than once this year. A clinic with $2 million of compliant, physician-supervised weight loss revenue and a clinic with $2 million sourced from a gray-market supplier can look identical on a P&L. They will not look identical in diligence. More on preparation shortly.

M&A, Translated for Aesthetics Owners

“Mergers and acquisitions” sounds like something that happens to companies with ticker symbols. In this industry, it usually describes a more specific consolidation strategy: a private equity firm acquires a well-run, professionally managed practice as its “platform” (the foundation it builds on), then purchases smaller “add-on” practices and integrates them into a shared operating infrastructure. Platforms command premium multiples; add-ons are acquired at lower valuations and plugged into centralized marketing, purchasing, and administrative functions. Understanding which category a buyer places you in is the first order of business, because it frames every negotiation that follows.

A handful of other concepts come up in nearly every conversation:

• Adjusted EBITDA: earnings before interest, taxes, depreciation, and amortization, “normalized” for owner perks, one-time costs, and above- or below-market physician compensation. This is the number buyers multiply, and it is negotiated, not given.
• Quality of earnings (QoE): an accounting firm’s independent review of that adjusted EBITDA. Consider it an independent assessment of your financials; buyers trust it far more than anything you produce yourself.
• MSO/PC structure: in states with corporate practice of medicine (CPOM) restrictions, such as California, Texas, and New York, a non-physician investor generally cannot own the medical practice directly. The buyer instead acquires a management services organization that contracts with a physician-owned professional corporation. Getting this wrong can sink a deal, or worse, surface as a regulatory problem two years after closing.
• Rollover equity: the portion of your proceeds reinvested into the buyer’s platform, commonly 25% to 40% in PE deals. This is your “second bite of the apple.”
• Letter of intent (LOI): a mostly nonbinding term sheet that grants the buyer exclusivity, often reducing the founder’s negotiating leverage and potentially resulting in unfavorable deal terms.

The Number on the LOI Is Not the Number You Keep

Here is the misconception we encounter most often: founders fixate on the headline multiple. “Ten times EBITDA” may sound like a clear win, but in practice, transaction structure, contractual terms, and post-closing purchase price adjustments determine more of your ultimate proceeds than the headline multiple itself.

Consider two simplified offers for a practice with $3 million of adjusted EBITDA, each asking the founder to roll the same $7.2 million into the buyer’s platform:

• Offer A: $30 million (or 10x); $10.8 million in cash at close, $7.2 million of rollover equity, and a $12 million earnout paid over three years, contingent on EBITDA growing 25% annually
• Offer B: $24 million (or 8x); $16.8 million in cash at close, $7.2 million of rollover equity, no earnout

Offer A has a higher headline valuation by $6 million, but Offer B provides $6 million more in cash at closing. When factoring in rollover equity, Offer B delivers $24 million in value at closing, compared to just $18 million under Offer A. To make up that difference, the founder would need to achieve the performance targets tied to Offer A’s $12 million earnout, which require EBITDA to grow 25% annually over three years. Importantly, those targets must be met under a buyer that controls the budget, hiring decisions, and accounting methods used to measure performance. Earnouts can and do pay out, but a dollar contingent on someone else’s operating decisions is worth less than a dollar wired at closing. Layer on a working capital peg set to the buyer’s advantage, an oversized indemnity escrow, or a “retrade” (when a buyer lowers its price late in diligence, after you’ve stopped talking to anyone else), and the gap widens further.

Notice the rollover is identical in both offers, and that is deliberate. Rollover equity is real value at close, and for many founders it ends up being the most lucrative piece of the deal: if the platform grows and sells at a higher multiple, that second bite can rival the first. It carries real risk as well, since you’ll hold a minority, illiquid stake whose value depends on the sponsor’s leverage, execution, and exit timing.

Rollover is not inherently bad, but that the terms around it, including whether you buy in at the same price per unit as the sponsor, your governance and tag-along rights, and where your equity sits in the distribution waterfall, deserve as much attention as the headline price.

Investment Banker, Broker, or Going It Alone?

That raises a question many founders do not ask until they’re already deep in a conversation with a buyer: who is actually representing you?

Many owners start alone. A buyer reaches out, the conversation goes well, and before long, an LOI is on the table. The problem is that a bilateral negotiation with a single counterparty offers no genuine price discovery; you are, in effect, accepting the first quote from the only contractor you called. The buyer understands this dynamic perfectly well, and it’s a major reason proprietary, “off-market” acquisitions are so prized by private equity sponsors.

Others hire a business broker, and for smaller, main-street businesses that is often the right call. The model works much like a real estate listing: the business is marketed broadly, and the broker helps close with whichever qualified buyer emerges. Institutional buyers work differently. A private equity sponsor evaluating a platform or add-on expects a well-positioned story, defensible adjusted EBITDA, and competing bidders, and it prices the deal accordingly when any of those is missing.

There is also a regulatory dimension many founders never hear about. Even in an asset sale, the rollover equity you receive in the buyer’s platform is generally a security, and selling the equity of a company is a securities transaction outright. Federal law does carve out an exemption that lets unregistered “M&A brokers” facilitate certain private company sales, but it is narrower than most people assume. It applies only below certain size thresholds (generally under $25 million of EBITDA or $250 million of revenue), only where the buyer takes control and actively runs the business, and it does not cover capital raises. It doesn’t override state securities laws, either. Step outside those lines, as an intermediary arranging a minority growth investment would, and the fee arrangement may be unenforceable; in some cases the transaction itself can be challenged. These distinctions can have significant consequences for a transaction. Investment banks operate as, or through, registered broker-dealers, which means no structure is off the table: a control sale, a minority investment, a recapitalization, or a debt raise.

A specialized investment banker approaches the same sale from the opposite direction. The work starts months before any buyer sees your name: normalizing EBITDA and anticipating QoE findings, preparing a confidential information memorandum (CIM) that tells your story in the language institutional buyers speak, and building a targeted buyer list, drawn from ongoing relationships with active investors, that spans PE platforms, family offices, strategics, and physician-led groups backed by private credit. Then the banker runs a process with real deadlines, so multiple bids arrive at the same time and terms get compared side by side. That competition creates leverage. Buyers notice it, too: a banker-run process tells them the numbers have already been pressure-tested and that pricing will be competitive, which tends to produce sharper first-round bids.

In practical terms, an experienced advisor should:

• Create competitive tension, so buyers bid against each other rather than against your patience
• Negotiate the full economics: cash at close, rollover terms, earnout definitions, working capital pegs, escrows, and your own employment agreement
• Run the diligence gauntlet (a virtual data room, hundreds of requests, weekly calls) while you keep running the business
• Spot retrade risk early and keep backup bidders warm until signing
• Coordinate your healthcare regulatory counsel, transaction attorney, and tax advisor so nothing falls through the cracks

That support in the final stages matters more than many founders realize. The most common way founders destroy value in a self-managed sale isn’t a poor negotiation; it’s operational distraction. The owner spends six months buried in diligence requests, provider schedules slip, monthly revenue softens, and the buyer points to the trailing dip as justification for a lower purchase price. Part of your banker’s job is making sure the business keeps performing while the deal gets done.

Not Selling Yet? Prepare Anyway

Exit planning doesn’t mean listing your business next quarter. It means building the flexibility to sell well whenever the timing makes sense, or to raise capital, or to recapitalize, or simply to run a better company. Meaningful preparation takes consistency, not a last-minute effort.

Key areas we would evaluate include:

• Financial hygiene: accrual-based monthly statements, clean separation of personal expenses, and reporting that matches how the business actually performs
• Entity structure: whether your MSO and clinical entities are set up correctly for your state’s CPOM rules, with management fees that hold up to scrutiny
• Provider economics: compensation plans, retention incentives, and restrictive covenants (whose enforceability varies widely by state)
• Concentration risk: how much revenue depends on you, or on one star injector, personally
• Service line compliance: sourcing and supervision for GLP-1s, peptides, and hormone therapy, documented in your EMR, whether that’s Aesthetic Record, Zenoti, Boulevard, or PatientNow
• The KPIs buyers actually price: revenue per provider hour, rebooking and retention rates, membership churn, and same-store growth

Some of these take a quarter to remediate. Others take a year. Discovering them during confirmatory diligence, with a buyer’s exclusivity clock running, is the expensive way to learn about them.

We’ve worked with founders who meaningfully increased their enterprise value without changing a single treatment on the menu. What changed was the clarity of the story and the quality of the numbers behind it.

Aesthetics Is Not Traditional Healthcare, and Your Advisor Should Know the Difference

It is easy to assume any advisor with a healthcare background can sell an aesthetics business. But medical aesthetics behaves unlike most of healthcare: it’s consumer-facing and service-intensive, blending clinical credibility with brand equity, community loyalty, and team culture in proportions that rarely show up in traditional provider services. Margins hinge on injector productivity and patient retention as much as on pricing or product cost. A beloved nurse injector walking out the door can move EBITDA more than a fee-schedule cut moves a typical physician practice.

Generalist advisors often miss these nuances. They underestimate how personality-driven these businesses are. They don’t know how to separate MSO and clinical P&Ls, or how a buyer will view your weight loss line after this year’s FDA activity. They may also steer you toward buyers who don’t understand (or respect) what makes your business work, which can be painful for your team long after the wire hits.

That’s why Skytale Group built a dedicated practice focused on medical aesthetics, cash-pay wellness, and performance medicine. We understand the sector from a transactional standpoint and from an operator’s perspective, and we structure outcomes that reflect both the financial value of the business and the founder’s vision for what it becomes next.

Timing, the Fourth Quarter, and Where to Start

There is also a seasonal consideration. For most aesthetics businesses, October through December is the busiest stretch of the year; patients want to look their best for holiday parties and New Year’s photos, and your schedule fills with Botox and filler appointments. It’s also when founders start mapping out the next year, and when buyers and lenders finalize their 2027 deployment plans. Preparation that starts this winter can realistically support a market launch in the first half of next year, with a full year of clean 2026 financials behind it.

If you’re considering a sale, or simply want to know what your business might be worth, the next step is uncomplicated: start a conversation. That is not a commitment to a process. It is an opportunity to get informed. Understand the market. Know your alternatives. Find out where your business is strong and where it needs work.

The window is open. Capital is available, buyer interest is high, and aesthetics continues to outpace much of healthcare services. But market conditions can change. Rates move, multiples compress, regulators change the rules mid-game, and consolidation eventually matures. The founders who come out ahead treat M&A as a strategy, not a reaction.

When the time comes, you want to lead the process, not just participate in it.